organization · Reporting owner
Vickers Venture Fund VI Pte Ltd
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | 10% owner | February 14, 2025 | February 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date February 14, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Vickers Venture Fund VI Pte. Ltd. | 2,050,902 |
Last balance in matching sequence
After 2025-02-14 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-02-14 · Conversion · Acquired 1,637,411 · Balance 1,637,411 F1: The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date. F2: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. F3: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Row 2 · 2025-02-14 · Conversion · Acquired 413,491 · Balance 2,050,902 F4: The Series B Convertible Preferred Stock of the Issuer automatically converted on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Convertible Preferred Stock had no expiration date. F2: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. F3: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vickers Venture Fund VI Pte. Ltd. | 0 |
Reported balance
After 2025-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-14 · Conversion · Disposed 13,875,429 · Balance 0 F1: The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date. F2: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. F3: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vickers Venture Fund VI Pte. Ltd. | 0 |
Reported balance
After 2025-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-14 · Conversion · Disposed 3,503,919 · Balance 0 F4: The Series B Convertible Preferred Stock of the Issuer automatically converted on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Convertible Preferred Stock had no expiration date. F2: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. F3: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date.
F2: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI.
F3: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F4: The Series B Convertible Preferred Stock of the Issuer automatically converted on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Convertible Preferred Stock had no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Scilex Holding Co
Report date November 10, 2022 · Filed November 16, 2022
Jointly reported with Vickers Venture Fund VI (Plan) Pte Ltd, Chi Jeffrey, Ho Chris
Section 16 reporting ended · disclosed 2022-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2027-11-10 | IndirectBy Vickers Venture Fund VI Pte Ltd | 901,000 |
Reported balance
After 2022-11-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-10 · Other · Disposed 5,261,840 · Balance 901,000 F1: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I F2: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2027-11-10 | IndirectBy Vickeres Venture Fund VI (Plan) Pte Ltd | 99,000 |
Reported balance
After 2022-11-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-10 · Other · Disposed 578,160 · Balance 99,000 F1: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I F2: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I
F2: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 19, 2025 21:48 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,503,919 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023287 · ownership.xml · derivative · entry 4 Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Vickers Venture Fund VI Pte. Ltd. Disclosed balance after: 0 Underlying: Common Stock · 413,491 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series B Convertible Preferred Stock of the Issuer automatically converted on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.exercise_date: The Series B Convertible Preferred Stock of the Issuer automatically converted on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.expiration_date: The Series B Convertible Preferred Stock of the Issuer automatically converted on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. F3 · ownership.nature: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:48 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | ConversionSeries A Convertible Preferred Stock · Derivative | 13,875,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023287 · ownership.xml · derivative · entry 3 Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Vickers Venture Fund VI Pte. Ltd. Disclosed balance after: 0 Underlying: Common Stock · 1,637,411 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. F3 · ownership.nature: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:48 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | ConversionCommon Stock | 413,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023287 · ownership.xml · nonDerivative · entry 2 Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Vickers Venture Fund VI Pte. Ltd. Disclosed balance after: 2,050,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series B Convertible Preferred Stock of the Issuer automatically converted on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. F3 · ownership.nature: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:48 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | ConversionCommon Stock | 1,637,411 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023287 · ownership.xml · nonDerivative · entry 1 Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Vickers Venture Fund VI Pte. Ltd. Disclosed balance after: 1,637,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. F3 · ownership.nature: (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| November 10, 2022 Filed Nov 16, 2022 02:47 UTC | Scilex Holding Co VCKAU · Entity 7345 | OtherWarrants · Derivative | 578,160 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001104659-22-119278 · tm2229408-1_4seq1.xml · derivative · entry 2 Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner · See footnote (1) Vickers Venture Fund VI (Plan) Pte Ltd · CIK 0001839160 · See footnote (1) Chi Jeffrey · CIK 0001839163 · See footnote (1) Ho Chris · CIK 0001838628 · See footnote (1) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vickeres Venture Fund VI (Plan) Pte Ltd Disclosed balance after: 99,000 Underlying: Common Stock · 578,160 shares Expires 2027-11-10 F1 · kind: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I F2 · kind: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. F2 · price: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. Read SEC document |
| November 10, 2022 Filed Nov 16, 2022 02:47 UTC | Scilex Holding Co VCKAU · Entity 7345 | OtherWarrants · Derivative | 5,261,840 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001104659-22-119278 · tm2229408-1_4seq1.xml · derivative · entry 1 Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner · See footnote (1) Vickers Venture Fund VI (Plan) Pte Ltd · CIK 0001839160 · See footnote (1) Chi Jeffrey · CIK 0001839163 · See footnote (1) Ho Chris · CIK 0001838628 · See footnote (1) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vickers Venture Fund VI Pte Ltd Disclosed balance after: 901,000 Underlying: Common Stock · 5,261,840 shares Expires 2027-11-10 F1 · kind: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I F2 · kind: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. F2 · price: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.